RxDoctor Payments Data

Marie Maitre, PA

Physician Assistant · Dallas, TXNPI 1295735900

Payments from drug & device makers

$9,664in general payments, 2019–2025

Across 42 payments — averaging $230.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Janssen Scientific Affairs, LLC$4K
  • Pfizer$1K
  • Lilly USA, LLC$1K
  • Johnson & Johnson$1K
  • Amgen$504
  • GSK$323
  • plus $649 from 6 others

What the payments were for

  • Consulting fees$2,17523%
  • Speaking & faculty fees$5,04052%
  • Travel & lodging$3153%
  • Food & beverage$2,13322%

General payments by program year

21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,664 in reported general payments places this provider in the 95th percentile of 8,308 physician assistant providers in Texas.

See all physician assistant providers in Texas

Medicare billing

Part B allowed, 2024
$7,732
Medicare patients
71
Services billed
125

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EnbrelEtanercept75$563,415
HumiraAdalimumab70$499,838
Enbrel SureclickEtanercept15$109,153
OrenciaAbatacept12$64,799
Hydroxychloroquine Sulfate76$3,963
Leflunomide62$3,938
Azathioprine28$2,551
Cevimeline Hcl14$2,510
Mycophenolate Mofetil16$2,319
MethotrexateMethotrexate Sodium100$1,713
Diclofenac Sodium19$875
Sulfasalazine22$643
Sulfasalazine DrSulfasalazine18$570
Gabapentin37$354
Cyclobenzaprine Hcl33$239

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenEnbrel$504$563,41575 claims
AbbVieHumira$168$499,83870 claims
E.r. Squibb & Sons, L.L.C.Orencia$125$64,79912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,308 physician assistant providers in Texas.

Other physician assistant in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →